Caribou expects these PD-1 knockout allogeneic CAR T therapies may overcome durability concerns to deliver therapies that are as effective as autologous anti-CD19 CAR T therapies but at a fraction of the cost. Caribou was co-founded in 2011 by, among others, CRISPR pioneer and Nobel laureate Jennifer Doudna.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
99,00 €
only 8,25 € per issue
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
About this article
Cite this article
Caribou’s first CRISPR CAR-T impresses.
Nat Biotechnol 40, 807 (2022). https://doi.org/10.1038/s41587-022-01371-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01371-6
